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Abstract- Some adipocytokines are cardioprotective or pro-inflammatory for thecardiovascular system. 
Chronic infection with Chlamydia pneumonia (C. pneumoniae) and Helicobacter pylori (H. pylori) has been 
also considered as novel risk factors for atherosclerosis. The main aim of the current population-based study 
is to investigate the potential link between circulating adipocytokines and Chlamydia pneumonia or H.  pylori 
IgG seropositivity. A total of 250 healthy postmenopausal women who participated in a prospective cohort 
study were evaluated for IgG antibodies directed against C. pneumoniae and H. pylori. Omentin-1, visfatin, 
adiponectin, and high-sensitivity C-reactive protein were measured by highly specific enzyme-linked 
immunosorbent assay methods. The prevalence of IgG antibodies against C. pneumoniae and H. pylori 
among the studied population was 20.4% (51 women) and 57.2% (143 women), respectively. There were no 
significant differences in adipocytokine levels between H. pylori IgG seropositive and H. pylori seronegative 
subjects. Similar results for visfatin and omentin-1 were found when C. pneumoniae IgG seropositive were 
compared with C. pneumoniae IgG seronegative subjects. However, in general, linear model adjusted for age; 
body mass index and hs-CRP levels revealed asignificant difference between C. pneumoniae seropositive and 
C. pneumoniae seronegative subjects for circulating adiponectin. In conclusion, C. pneumonia IgG 
seropositivity was associated with higher adiponectin levels in postmenopausal women. The elucidation of 
interaction mechanism of C. pneumonia and a cardioprotective adipocytokine (adiponectin) will be useful in 
future therapeutic strategies. 
© 2016 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran, 2016;54(12):771-777. 
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Introduction 
 
A growing body of clinical evidence has indicated 
that the increased size of adipocytes and chronic low-
grade inflammation within theadipose tissue can alter 
the secretion and production of a variety of biologically 
active protein factors called adipocytokines (1). 
Some adipocytokines have recently become the 
focus of research on the role of obesity in atherosclerosis 
because they have important complex interactions with 
endothelial cells, arterial smooth muscle cells, and 
macrophages in vessel walls (2,3). 
Adiponectin is a good adipocytokine that has 
attracted great attention due to its antidiabetic, anti-
inflammatory, anti-thrombotic, and anti-atherogenic 
properties (4).It has been hypothesized that this 
adipocytokine may be a cardioprotective adipocytokine 
(5-7). 
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Omentin-1 is a novel 34 kDa adipocytokine, which 
not only regulates energy metabolism but also is 
implicated in the complex interactions between fat and 
heart (8). In fact, this adipocytokine is highly expressed 
and secreted by epicardial adipose tissue (9). The studies 
on the effect of recombinant omentin-1 on 
cardiomyocyte contractile function and insulin action, 
suggest that lower omentin-1 levels may be implicated 
in the pathogenesis of cardiac dysfunction in type 2 
diabetes mellitus (10). 
Visfatin, which is identical to the ‘‘pre-B-cellcolony-
enhancing 91 factor (PBEF1)’’ and 
‘‘nicotinamidephosphoribosyltransferase (Nampt),’’ is 
secreted abundantly by the visceral fat of humans and 
mice and mimics the action of insulin (11). Visfatin was 
reported to be involved in cardiovascular diseases 
(12,3). However, whether this adipocytokine is a 
cardioprotective or a risk factor for ischemic heart 
disease remains uncertain (14). 
Chronic infection with C. pneumonia, H. pylori, and 
persistent viruses such as herpes simplex virus 1(HSV-
1) and cytomegalovirus (CMV) has been also considered 
as novel risk factors for atherosclerosis and the 
subsequent cardiovascular diseases (15-17). A growing 
body of evidence has demonstrated a contributory role 
for C. pneumonia, an obligate intracellular organism, in 
the pathogenesis of coronary artery disease, stroke, and 
peripheral atherosclerosis (18-20). Although the 
contributory role of H. pylori in the pathogenesis of 
atherosclerosis and ischemic heart disease remains 
enigmatic (21), this ubiquitous gram-negative bacterium 
has been shown to be associated with coronary artery 
disease and stroke (22,23). Chronic infection with H. 
pylori may be a risk factor for early coronary 
atherosclerosis regardless of traditional cardiovascular 
risk factors (24). 
Despite the rapidly growing number of studies about 
the involvement of C. pneumoniae infection and H. 
pylori in cardiovascular diseases through the 
atherosclerotic changes in thevasculature that arise from 
thechronic inflammatory response (21,24), the 
pathogenic mechanisms are not fully understood.  
Adipocytes like endothelial cells, monocytes, and 
hepatocytes produce inflammatory cytokines in response 
to infection with a range of different viral and bacterial 
organisms (25). The increased production of IL-6 and 
TNF-alpha by infected abdominal adipocytes and 
secondarily release of CRP by the liver may contribute 
to the initiation of atherosclerosis. In another aspect, the 
infection-induced inflammatory response may influence 
the adipocytes and alter the release of adipocytokines. 
Theoretically, this alteration in the secretion of 
adipocytokines may lead to increase cardiovascular risk. 
The main aim of the current population-based study 
is to investigate the potential link between circulating 
adipocytokines and C. pneumonia or H. pylori IgG 
seropositivity. To the best of our knowledge, the current 
study is the first to evaluate omentin-1 and visfatin in 
relation to chronic infection with Chlamydia 
pneumoniaand H. pylori. 
 
Materials and Methods 
 
Community sampling  
In an extension arm of the Iranian Multicentral 
Osteoporosis Study, a community-based longitudinal 
study, an age-stratified random sample of 
postmenopausal women was selected from 13 clusters in 
Bushehr Port (the center of Bushehr province, which has 
the longest border with the Persian Gulf). All were 
community dwelling and ambulatory. The study design 
was described previously in detail (12). The participants 
in the current study were a subset of 250 
postmenopausal women who participated in the 
extension arm of the Iranian Multicentral Osteoporosis 
Study. The study was approved by the medicalethical 
committee of Bushehr University of Medical Sciences, 
and written informed consent was obtained from all 
subjects. 
 
Physical examinations 
A stadiometer was used to measure the subjects’ 
height and weight. Heavy outer garments and shoes 
were removed before the participants’ height, and 
weight was measured. Their body mass index (BMI) 
was calculated. Waist circumference was defined at the 
midway level between the costal margins and the iliac 
crests. Hip circumference was measured at the level of 
the greater trochanters. 
 
Laboratory measurements 
A fasting blood sample was taken. All the samples 
were promptly centrifuged and separated, and analyses 
were carried out at the Persian Gulf Health Research 
Center. 
C-reactive protein (CRP) was measured by using 
CRP HS enzyme-linked immunosorbent assay (ELISA) 
(DRG International), a highly sensitive (hs) CRP assay. 
The concentration of 0.1 mg/l for CRP was estimated to 
be the lowest detectable concentration in the CRP HS 
ELISA assay. According to theinter-assay coefficient of 
variation (CV)<20%, the functional sensitivity of CRP 
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measurement was determined to be 0.1 mg/l. 
Serum omentin-1 concentrations were measured 
using manualomentin-1 (human) detection (ELISA kit 
[intelectin-1 (human) ELISA kit, Apotech Corporation, 
Switzerland]). The detection limit of the assay was 0.4 
ng/mL (range 0.5 to 32 ng/mL). The mean intra-assay 
and inter-assay CVs of the omentin-1 assay were 4.51% 
to 7.4% and 4.19% to 9.27%, respectively. The 
antibodies used in this kit are specific to 
themeasurement of natural and recombinant human 
omentin-1. To detect visfatin in the serum samples, 
commercially (Cat. No. V0523EK) available enzyme-
linked immunosorbent assay kit (Adipo-Gen, Seoul, 
Korea) was used according to the manufacturer's 
instructions. The assay sensitivity for visfatin was 0.10 
ng/mL; the intra- and inter-assay coefficients of variance 
were 3.8–5.5% and 6.4–9.5%, respectively.  
To detect adiponectin in the serum samples, 
commercially (Cat. Q6No.AG-45A-0001EK-KI01) 
available enzyme-linked immunosorbentassay kits 
(AdipoGen, Incheon, Korea) were used according to the 
manufacturer's instructions. The limit of detection of the 
assay was 100 pg/mL; the intra- and inter-assay 
coefficients of variance were2.9% to 3.8% and 2.8% to 
5.5%, respectively. 
IgG antibodies against C. pneumoniae were 
measured by a commercial test kit (DRG Instruments 
GmbH, Germany). The kit is based on an indirect solid-
phase enzyme immunoassay with horseradish 
peroxidase as a marker enzyme; the positivity threshold 
was enzyme immunounits>45. Sera were screened for 
IgG antibodies against H. pylori with an ELISA kit 
(RadimSpA, Italy), and the samples were considered 
positive when IgG values were higher than 30 RU/ml for 
H. pylori. 
 
Statistical methods 
Normal distribution of the data was controlled with 
the Kolmogorov-Smirnov test. The significance of the 
difference in the results of any two groups was 
determined by chi-square analysis using 2×2 
contingency tables for categorical variables. A two-
tailed t-test was used to compare the mean values across 
groups. We found that log transformation of 
adipocytokines and hs-CRP levels gave a better fit to a 
Gaussian distribution. The geometric mean for those 
biochemical variables was defined as the arithmetic 
mean of the log-transformed data±SD, raised to the 
power of 10. 
The general linear model (GLM) univariate 
procedure was used for regression analysis and analysis 
of variance for one dependent variable (each 
adipocytokines levels) by IgG seropositivity for 
Chlamydia pneumonia or H. pylori (as theindependent 
variable). The covariates were age, BMI and hs-CRP 
levels for GLM models of circulating adipocytokines. 
Probability values<5% were considered statistically 
significant. All statistical analyses were performed using 
the PASW Statistics GradPack 18 (SPSS Inc., Chicago, 
IL). 
 
Results 
 
Table 1 shows the baseline characteristics of the 
studied postmenopausal women, stratified by IgG 
seropositivity against C. pneumoniaeand H. pylori. The 
mean age (mean±SD) of the women was 58.87±8.02 
years. The prevalence of IgG antibodies against C. 
pneumonia and H. pylori among the studied population 
was 20.4% (51 women) and 57.2% (143 women), 
respectively.  
There were no significant differences in age, 
anthropometric measures and adipocytokine levels 
between H. pylori IgG seropositive and H. pylori 
seronegative subjects (Table 1, P>0.05). Similar results 
were found when C. pneumoniaeIgG seropositive were 
compared with C. pneumoniaeIgGseronegative subjects, 
except for thesignificant difference in serum adiponectin 
levels.  
Bivariate correlation analysis showed a correlation 
between circulating adiponectin and age (r=0.187, 
P=0.001), BMI (-0.160, P=0.004), and hsCRP levels 
(r=-0.127, P=0.022). However, no significant 
correlations were found between omentin-1 and age, 
BMI, and hs-CRP levels (P>0.05). Visfatin levels were 
correlated with BMI (r=0.160, P=0.004) and hs-CRP 
levels (r=0.283, P<0.0001). 
GLM analyses for omentin-1 and visfatin levels 
showed no significant differences between C. 
pneumoniae seropositive and C. pneumoniae 
seronegative subjects after adjustment for covariates 
(age, BMI, and hs-CRP levels). However, age-adjusted 
adiponectin levels were significantly higher in C. 
pneumoniaeseropositive than C. 
pneumoniaeseronegative subjects. This significant 
difference remained after further adjustment for BMI 
and hs-CRP levels (P=0.005, Table 2). 
GLM analyses for omentin-1 and visfatin and 
adiponectin levels showed no significant differences 
between H. pylori seropositive and H. pylori 
seronegative women (P>0.05, Table 2). 
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Table 1. The baseline characteristics of the studied postmenopausal women, stratified by IgG 
seropositivity against C. pneumoniae and H. pylori 
 Chlamydia pneumoniaIgG H. pyloriIgG 
 Positive Negative P.value Positive Negative P.value 
Age, y 59.61±8.78 58.68±7.82 0.464 58.24±7.55 59.88±8.61 0.114 
Waist 
circumference, cm 
99.25±12.34 99.19±10.19 0.970 99.39±9.90 98.95±11.54 0.745 
Bady mass index, 
kg/m2 
28.07±5.23 28.32±4.60 0.738 28.52±4.57 27.93±4.92 0.338 
Waist-to-hip ratio 0.92±0.08 0.92±0.06 0.752 0.92±0.06 0.92±0.07 0.588 
Omentin-1, 
ng/mL, * 
10.78±2.55 11.29±2.19 0.720 11.41±2.07 10.87±2.54 0.650 
Adiponectin, 
µg/mL* 
12.97±1.59 10.31±1.56 0.002 10.59±2.07 11.22±1.62 0.342 
Visfatin,  
ng/mL* 
2.44±1.83 2.79±1.90 0.189 2.64±1.89 2.76±1.86 0.621 
hs-CRP, 
mg/L* 
1.66±2.37 1.92±2.77 0.365 2.05±2.48 1.64±2.95 0.078 
Data are given as means±SD 
*Geometric mean±SD 
 
 
Table 2. Age-, body mass index-, and hs-CRP adjusted adipocytokine levels by IgG 
seropositivity of Chlamydia pneumoniaand H. pylori in postmenopausal women in GLM 
analyses 
 C. pneumoniaeIgG H. pyloriIgG 
 Positive Negative P.value Positive Negative P.value 
Adiponectin, µg/mL 12.70±1.59 10.35±1.55 0.005 10.59±1.58 10.59±1.58 0.470 
Omentin-1, ng/mL 10.78±2.55 11.22±2.18 0.739 11.40±2.07 11.40±2.07 0.723 
Visfatin, ng/mL 2.41±1.77 2.77±1.90 0.246 2.64±1.89 2.64±1.89 0.423 
Data are geometric mean±standard deviation 
 
 
 
Discussion 
 
In the current study, we found that postmenopausal 
women with C. pneumoniaIgG positive antibodies had 
significantly higher levels of adiponectin compared with 
Chlamydia pneumonia IgG negative postmenopausal 
women. This association was independent of hsCRP and 
obesity measures. 
C. pneumoniahas now been considered a novel risk 
factor for atherosclerosis since this organism was 
directly detected in atheroma (27,28). It has been shown 
that PPAR alpha and PPAR gamma pathways are 
involved in C. pneumonia-induced macrophage-derived 
foam cell formation, a typical pathological feature of 
early atherosclerosis (29,30). Adiponectin can suppress 
lipid accumulation in macrophages and inhibit 
macrophage-derived foam cell formation (31). 
Therefore, the observed increased circulating levels of 
adiponectin in the current study may act as a counter-
regulatory mechanism of attenuating detrimental effect 
of C. pneumoniain atherosclerosis development via 
macrophage-derived foam cell formation. 
Kim et al., investigated the change of PPAR gamma 
after the infection of the human coronary artery smooth 
muscle cells with C. pneumonia (32). They found that C. 
pneumonia could upregulate the expression of PPAR 
gamma mRNA and protein in vascular smooth muscle 
cells (32). As an important member of the nuclear 
receptor superfamily, PPAR gamma is a modulator of 
the inflammatory response in vessel walls (33,34).  
PPAR gamma can induce the transcriptional 
activation of the adiponectin gene (35). It has been 
shown that PPAR-alpha activation not only reduced 
inflammation and the expression of macrophage-specific 
genes but also upregulated adiponectin receptors in 
white adipose tissue. Moreover, dual PPAR-alpha and 
PPAR-gamma activation increased adiponectin and its 
receptors (36). These experiments provide a plausible 
explanation for the observed significant association 
between C. pneumonia IgG seropositivity and elevated 
adiponectin (as a good adipocytokine) levels. In fact, the 
observed higher circulating adiponectin in chronic 
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infection with C. pneumoniamight be a physiological 
compensation and adaptation to protect vasculature from 
atherosclerosis development. 
It has been reported that a range of viral and bacterial 
organisms are able to infect human adipocytes and 
induce inflammatory cytokines in vitro (25). Shi et al., 
demonstrated that C. pneumoniacould infect murine pre- 
and post-differentiated adipocytes and impair insulin 
signaling via an inflammatory pathway (37). However, 
none of theinfective or inactivated microorganisms 
including C. pneumoniainduced significant changes in 
adiponectin production in adipocytes (25). Hence, 
positive association between C. pneumoniaand 
circulating adiponectin in our study might be beyond 
direct involvement of adipocytes by this organism. 
Recently, the effects of new CIq/TNF-related protein 
(cartonectin) with structural homologies to adiponectin 
on the adipocytokine secretions by adipocytes were 
studied (38,39). Further study is warranted to determine 
whether C. pneumoniainfection can contribute to 
cartonectin secretion because this novel adipocytokine is 
expressed in human adipocytes and regulated by 
metabolic and infection-related factors (39). 
In addition, we did not found asimilar association 
between C. pneumoniaIgG seropositivity and the other 
novel adipocytokines like omentin-1 and visfatin. Since 
there is no previously reported study in C. 
pneumoniainfection in relation with these novel 
adipocytokines, further works are required to confirm 
the results of the current study. 
In our study, we found that H. pylori IgG 
seropositivity was not associated with omentin-1, 
visfatin, and adiponectin. Although there is no study 
regarding H. pylori infection in relation to omentin-1 
and visfatin in themedical literature, in agreement with 
the results of the current study, two independent 
researchers reported circulating adiponectin levels were 
not different between H. pylori positive and H. pylori 
negative patients (40,41). Similar levels of adiponectin 
in H. pylori IgG antibodies positive and negative in 
patients who underwent endoscopy for dyspepsia were 
reported by Ando et al., (40). However, eradication of 
H. pylori increased total and high molecular weight 
adiponectin levels in these patients (40). It has been 
hypothesized that it was modulation of gut microbiota 
by H. pylori eradication regimens responsible for the 
observed increased levels of adiponectin, in an H. pylori 
independent infectious process (42).We acknowledge 
several limitations in our study. We used IgG 
seropositivity against C. pneumoniaeand H. pylori as a 
marker of prior infection. These serologic studies may 
not reflect persistent, chronic active or reinfection. 
Although the participants of the current study were 
healthy postmenopausal women who were randomly 
selected from a general population, the under or over 
estimating C. pneumoniaeor H. pylori infections using 
serological tests was possible because of the difficulty in 
obtaining relevant clinical data in such setting. 
Currently, there is no valid marker to show the presence 
of chronic infection with C. pneumoniaein 
seroepidemiological studies (43). However, the 
standardization and validation of nucleic acid 
amplification tests to show DNA evidence of infection 
may offer the potential for identifying currently infected 
patients in the future studies. Interestingly, it has been 
reported that there is a significant relationship between 
organism-specific DNA or antigens in coronary arteries 
obtained at autopsy and levels of pre-existing C. 
pneumoniae-specific IgG antibody titers (44). We had 
no longitudinal data to assess thelonger-term association 
between C. pneumoniae seropositivity with adiponectin. 
Thus, the cross-sectional study design of our study did 
not allow us to examine the cumulative effects of 
adipocytokines and chronic C. pneumoniae over the 
course of the participants’ lives. Although this study is 
the first population-based study to investigate a link 
between C. pneumoniae or H. pylori seropositivity and 
adipocytokines, its findings should be confirmed in 
further human studies with larger samples.  
In conclusion, C. pneumonia IgG seropositivity was 
associated with higher adiponectin levels in 
postmenopausal women. This association should be 
validated in prospective studies. If confirmed, the 
knowledge of how theinteraction between prior 
infections with pathogenic organisms involved in 
atherosclerosis with a cardioprotective adipocytokine 
(adiponectin) occurs will be useful in future therapeutic 
strategies. Undoubtedly, the elucidation of Chlamydia 
pneumonia and adipocytokines interface is a promising 
target for the treatment and prevention of cardiovascular 
diseases. 
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